Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
Letter to the Editor: Efficacy and safety of the generic forms of sofosbuvir/ledipasvir in chronic hepatitis C virus adolescents in Upper Egypt
Nahed A Makhlouf, Department of Tropical Medicine and Gastroenterology, Medical Director of Liver Transplantation Program, Al-Rajhi Liver Hospital, Faculty of Medicine, Assiut University, Assiut 71515, Egypt
Author contributions: Makhlouf NA wrote the original draft, re-reviewed and edited the manuscript according to reviewer’s comments, and approved the final version of the manuscript.
Conflict-of-interest statement: Dr. Makhlouf has nothing to disclose.
Corresponding author: Nahed A Makhlouf, MD, Professor, Department of Tropical Medicine and Gastroenterology, Medical Director of Liver Transplantation Program, Al-Rajhi Liver Hospital, Faculty of Medicine, Assiut University, Kornish Al-Ibrahimeya Street, Assiut 71515, Egypt. nahedmak@yahoo.com
Received: January 21, 2026
Revised: January 28, 2026
Accepted: February 5, 2026
Published online: August 27, 2026
Processing time: 222 Days and 17.5 Hours
Revised: January 28, 2026
Accepted: February 5, 2026
Published online: August 27, 2026
Processing time: 222 Days and 17.5 Hours
Core Tip
Core Tip: Using brand forms of direct acting antivirals (DAAs) against hepatitis C virus (HCV) is limited in low- and middle-income countries. Generic forms of DAAs were widely used in adults. Few studies addressed this issue in children and adolescents in Egypt. We support the use of the generic forms of sofosbuvir/ledipasvir in HCV infected children and adolescents.